Verteporfin
- Generic Name
- Verteporfin
- Brand Names
- Visudyne
- Drug Type
- Small Molecule
- Chemical Formula
- C41H42N4O8
- CAS Number
- 129497-78-5
- Unique Ingredient Identifier
- WU713D62N9
- Background
Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces hi...
- Indication
For the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis syndrome. Verteporfin can also be used to destroy tumors.
- Associated Conditions
- Subfoveal Choroidal Neovascularization (CNV)
- Associated Therapies
- -
Photo-induction as a Means to Improve Cisplatin Delivery to Pleural Malignancies
- First Posted Date
- 2016-03-09
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Centre Hospitalier Universitaire Vaudois
- Target Recruit Count
- 1
- Registration Number
- NCT02702700
- Locations
- 🇨🇭
Oncology Department, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Vaud (VD), Switzerland
Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD
- Conditions
- Interventions
- First Posted Date
- 2015-05-29
- Last Posted Date
- 2017-07-26
- Lead Sponsor
- Duke University
- Registration Number
- NCT02457026
- Locations
- 🇺🇸
Duke Eye Center, Durham, North Carolina, United States
A Study Testing if Medicine Can Make Pigment Epithelium Detachments Regress and Stabilize the Vision in Eyes
- Conditions
- Interventions
- First Posted Date
- 2012-12-11
- Last Posted Date
- 2015-09-15
- Lead Sponsor
- Norwegian University of Science and Technology
- Target Recruit Count
- 9
- Registration Number
- NCT01746875
- Locations
- 🇳🇴
Department of Neuroscience, NTNU, Trondheim, Norway
Lucentis KAV Study
- Conditions
- Interventions
- First Posted Date
- 2012-04-04
- Last Posted Date
- 2012-04-04
- Target Recruit Count
- 51
- Registration Number
- NCT01570608
- Locations
- 🇦🇹
Department of OPhthalmology Medical center east, Vienna, Austria
🇦🇹Department of Ophthalmology Rudolf foundation Clinic, Vienna, Austria
🇦🇹Department of Ophthalmology, Hospital Hietzing, Vienna, Austria
Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy
- Conditions
- Interventions
- First Posted Date
- 2011-03-29
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Jang Won Heo
- Target Recruit Count
- 34
- Registration Number
- NCT01325181
- Locations
- 🇰🇷
• Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Gyeonggi-do, Korea, Republic of
Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis
- Conditions
- Interventions
- First Posted Date
- 2007-10-19
- Last Posted Date
- 2009-04-16
- Lead Sponsor
- Barnes Retina Institute
- Target Recruit Count
- 30
- Registration Number
- NCT00546936
- Locations
- 🇺🇸
Barnes Retina Institute, St. Louis, Missouri, United States
🇺🇸Macula-Retina-Vitreous Service, Midwest Eye Institute, Indianapolis, Indiana, United States
Ranibizumab and Reduced Fluence PDT for AMD
- First Posted Date
- 2007-09-11
- Last Posted Date
- 2013-06-07
- Lead Sponsor
- Texas Retina Associates
- Target Recruit Count
- 60
- Registration Number
- NCT00527475
- Locations
- 🇺🇸
California Retina Consultants & Research Foundation, Santa Barbara, California, United States
🇺🇸Associated Retinal Consultants, Ann Arbor, Michigan, United States
🇺🇸Texas Retina Associates, Arlington, Texas, United States
Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)
- Conditions
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2011-06-02
- Lead Sponsor
- QLT Inc.
- Target Recruit Count
- 162
- Registration Number
- NCT00492284
- Locations
- 🇺🇸
Retina Centers, PC, Tucson, Arizona, United States
Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2007-05-15
- Last Posted Date
- 2020-11-06
- Target Recruit Count
- 31
- Registration Number
- NCT00473642
- Locations
- 🇺🇸
Eagle Mountain Vision, Tulsa, Oklahoma, United States
Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD
- Conditions
- First Posted Date
- 2007-01-26
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Retinal Consultants Medical Group
- Target Recruit Count
- 30
- Registration Number
- NCT00426998
- Locations
- 🇺🇸
Retinal Consultants Medical Group, Inc., Sacramento, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.